High-dose @entity888 treatment alters presynaptic XXXX and @entity2227 immunoreactivity.

@entity2227 @entity137 @entity1246 @entity888 @entity535 @entity935 @entity191 @entity590 @entity35 @entity2955 @entity221
The goal of this study was to determine if high-dose @entity888 treatment altered presynaptic immunoreactivity for the @entity535 neurotransmitters @entity1246 and @entity2227 within the basal ganglia. @entity888 (15 mg/kg every 6 h, four doses) treatment in @entity35 resulted in severe @entity221 and a long-lasting (four weeks) depletion of striatal @entity935 content (>80%). Severe @entity935 loss correlated with a decrease in the density of presynaptic immunolabeling for @entity1246 one week post-drug, and an increase after four weeks. Although no changes were seen in presynaptic striatal @entity2227 immunoreactivity, there was a significant increase in the percentage of @entity2227 -immuno-positive terminals associated with perforated postsynaptic densities. @entity35 given the same dose of @entity888 but prevented from becoming hyperthermic showed less severe @entity935 depletions and a lack of ultrastructural or immunocytochemical changes. In addition, induction of @entity221 in the absence of drug decreased immunolabeling within mitochondria, but had no effect on @entity935 content, morphology or nerve terminal immunoreactivity. Altered presynaptic @entity1246 immunolabeling and terminal size were found in both the striatum and globus pallidus, suggesting that dynamic changes occur in the striatopallidal pathway following @entity888 -induced @entity935 loss. In addition, ultrastructural changes in @entity2227 -positive synapses which have been correlated with increased synaptic activity were found. These results are similar to changes in @entity1246 and @entity2227 synapses that follow nigrostriatal @entity935 loss in @entity2955 -lesioned animals and in @entity191 , and provide the first direct evidence that @entity888 -induced @entity935 loss alters the GABAergic striatopallidal pathway. Exposure to either @entity888 or prolonged @entity590 decreased mitochondrial Immunoreactivity, indicating that @entity221 may contribute to @entity888 @entity137 by affecting energy stores.
